Scientific Advisory Board

Dr Ernie Harpur

Toxicologist, University of Newcastle

Following periods of doctoral and post-doctoral research in toxicology, Ernie spent 13 years in academia where his research interests centered on investigations of mechanisms of toxicity.  Ernie subsequently worked for 21 years in Drug Safety Assessment in pharmaceutical industry based in Europe and the USA, for the last 9 years as Global Head of Scientific Affairs and Regulatory Standards.

Professor Frank Bonner

Chief Executive
SC4SM

Professor Frank Bonner was appointed Chief Executive of Stem Cells for Safer Medicines in July, 2009 and led a successful funding effort with the private and public sectors which provided support for the current research campaign.

Dr Emyr Harries

Senior Scientific Officer and Policy Manager, UK Department of Health

Dr Emyr Harries is Senior Scientific Officer and Policy Manager at the UK Department of Health with responsibility for Cell Therapy, focusing on human stem cell use for therapeutic purposes such as stem cell transplantation and the emergence of Regenerative Medicine.

Dr Rob Thomas

Senior Lecturer, University of Loughborough

Dr Rob Thomas is a Senior Lecturer and EPSRC Early Career Fellow in Bio-manufacturing at Loughborough University. He is also associate director of the EPSRC Centre for Innovative Manufacturing in Regenerative Medicine led from the Centre for Biological Engineering at Loughborough University.

Professor Steve Dunnett

Professor, Brain Repair Group, University of Cardiff

Professor Stephen Dunnett is Professor of Neuroscience and Director of the Brain Repair Group at the School of Biosciences, Cardiff University. He originally trained in mathematics and in experimental psychology at Cambridge and London Universities. He was a lecturer in experimental psychology, reader in neurobiology, and founding scientific director of the Centre for Brain Repair in Cambridge University, before moving to a research chair at Cardiff University where he established the Brain Repair Group.

Dr Rob Buckle

Director of Science Programmes, MRC

Dr Rob Buckle is Director of Science Programmes at the UK Medical Research Council (MRC), which is the main Government agency responsible for UK biomedical research. Rob is also Director of the UK Regenerative Medicine Platform,a new £25M managed programme established by three UK research councils to deliver translational research that will drive new therapeutic approaches in regenerative medicine.

Dr Philip Newsome

Head of Cell Therapy, Birmingham University

Dr Phil Newsome is the Head of Cell Therapy and Clinical Director of the Birmingham University Stem Cell Centre. He is also Director of the state of the art Advanced Therapies Facility which is responsible for the production of cellular therapies.

Professor Kevin Park

Director, MRC Centre for Drug Safety Sciences

Kevin is currently Professor of Pharmacology, Head of the Institute of Translational Medicine at the University of Liverpool and Director of the M.R.C. Centre for Drug Safety Sciences.  Professor Park was awarded a Fellowship of the Royal College of Physicians in 2009 and is also a Commissioner on Human Medicines and a Fellow of the Academy of Medical Sciences.

Dr Joanne Bowes

Principal Scientist, AstraZeneca R&D;

Dr Joanne Bowes is a Principal Scientist and Leader of Secondary Pharmacology in the Global Safety Assessment (GSA) function of AstraZeneca R&D. She has a comprehensive understanding of the Drug Discovery and Development process from her experience of working in and supporting project teams across multiple therapeutic areas for the last 14 years.

Dr Helen Kuhlman

Lead Technologist, Medicines & Healthcare, TSB

A cell physiologist and pharmacologist by training, Helen has a 1st Class Honours degree in Biomedical Sciences, and a PhD from the Department of Medicine at the University of Leicester. She joined the Technology Strategy Board in 2010. Within the Technology Strategy Board Helen is involved in leading the overarching Medicines and Healthcare strategy and is responsible for the Biomedical Catalyst programme.

Dr James Sidaway

Principal Scientist
AstraZeneca

Dr James Sidaway is a Principal Scientist in Global Safety Assessment at AstraZeneca, specialising in Molecular Toxicology. James currently leads the AstraZeneca preclinical strategy for drug induced liver toxicity. He is a former chairman of the In Vitro Toxicology Society and is an honorary lecturer at the MRC Centre for Drug Safety Science at Liverpool University.

Dr Glyn Stacey

Director
UK Stem Cell Bank

Glyn has a background in microbiology and cancer research and has worked on the development of cell substrates for manufacture of biological medicines. He is currently Head of Division of Cell Biology and Imaging and Director for the UK Stem Cell Bank, a licensed clinical tissue bank, at the National Institute for Biological Standards and Control at South Mimms, UK.

Professor Tim Hammond

Consultant, pharmaceutical drug Discovery and Development

Professor Tim Hammond is a consultant with 35 years experience in pharmaceutical drug Discovery and Development. He was previously the Vice President of Safety Assessment in the UK for AstraZeneca.

Dr Colin Miles

Head of the Strategy, Industrial Biotechnology and Bioenergy, BBSRC.

Dr Colin Miles is Head of the Strategy for the Industrial Biotechnology and Bioenergy sector at BBSRC. In his current role, he leads a team to help increase the capacity and capability of the UK academic base in research, training and knowledge exchange activities in UK industrial biotechnology and bioenergy research.

Dr Adrian Roth

Section Head, Pharma Research, Hoffmann-La Roche

Dr Adrian Roth is heading the Mechanistic Safety Section within Roche’s Non-Clinical Safety Organisation. The group has established a wide variety of tools to experimentally address issues arising during all stages of drug development where potential organ toxicities arise.

Libby Dixon

R&D; Policy Officer, ABPI

Libby has been providing scientific and administrative support to SC4SM since August 2013, project managing the Phase 2 work and overseeing coordination of network activities.
The work with this consortium forms part of a wider role with the Association of the British Pharmaceutical Industry (ABPI).